FDA Approved: DABIGATRAN ETEXILATE — Supplemental Application (Major Pharmaceuticals)

View source ↗

Summary

The FDA approved a supplemental application for dabigatran etexilate (generic) submitted by Major Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Nonvalvular Atrial Fibrillation
• Pulmonary Embolism

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

SUPPL AP for DABIGATRAN ETEXILATE (DABIGATRAN ETEXILATE)